Secondary Logo

Journal Logo

Cancer-Related News from the CDC: Medical Costs and Productivity Losses of Cancer Survivors

Ekwueme, Donatus U. PhD; et al.

doi: 10.1097/01.COT.0000455798.08884.24
News
Free

Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention; K. Robin Yabroff, PhD, Health Economics Research on Cancer Workgroup, National Cancer Institute; Gery P. Guy, Jr., PhD, Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, CDC; Matthew P. Banegas, PhD, Health Economics Research on Cancer Workgroup; NCI; Janet S. de Moor, PhD, Health Economics Research on Cancer Workgroup, NCI; Chunyu Li, PhD, MD, Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, CDC; Xuesong Han, PhD, Health Economics Research on Cancer Workgroup, American Cancer Society; Zhiyuan Zheng, PhD, Health Economics Research on Cancer Workgroup, ACS; Anita Soni, PhD, Health Economics Research on Cancer Workgroup, Agency for Healthcare Research and Quality; Amy Davidoff, PhD, Health Economics Research on Cancer Workgroup, AHRQ; Ruth Rechis, PhD, Health Economics Research on Cancer Workgroup, Livestrong Foundation; Katherine S. Virgo, PhD, Health Economics Research on Cancer Workgroup, Emory University.

Figure

Figure

The number of persons in the United States with a history of cancer has increased from three million in 1971 to approximately 13.4 million in 2012, representing 4.6 percent of the population.1,2 Given the advances in early detection and treatment of cancer and the aging of the U.S. population, the number of cancer survivors is projected to increase by more than 30 percent during the next decade, to approximately 18 million.2,3

Cancer survivors face many challenges with medical care follow-up, managing the long-term and late effects of treatments,4 monitoring for recurrence, and an increased risk for additional cancers.4,5 These survivors also face economic challenges, including limitations in work and daily activities, obtaining health insurance coverage and accessing health care, and increasing medical care costs.

To estimate the annual medical costs and productivity losses among male and female cancer survivors and persons without a cancer history, CDC, along with other organizations, analyzed data from the 2008-2011 Medical Expenditure Panel Survey (MEPS), sponsored by the Agency for Healthcare Research and Quality. The results indicate that the economic burden of cancer survivorship is substantial among all survivors. For male cancer survivors, during 2008-2011, the average annual medical costs and productivity losses resulting from health problems per person and adjusted to 2011 dollars were significantly higher among cancer survivors than among people without a cancer history, by $4,187 and $1,459, respectively; for females, the estimated annual costs per person were $3,293 and $1,330 higher among cancer survivors than among persons without a cancer history, respectively.

These findings suggest the need to develop and evaluate health and employment intervention programs aimed at improving outcomes for cancer survivors and their families.

Back to Top | Article Outline

Study Methods

Data from the 2008-2011 MEPS (annual response rate was 53.5% to 59.3%) and the 2011 MEPS Experiences with Cancer Survivorship Survey6 (response rate of 90.0%) were analyzed. MEPS is an annual nationally representative survey of the U.S. civilian noninstitutionalized population that collects detailed information on demographic characteristics, health status, income, employment, and health care expenditures.

In 2011, cancer survivors (defined for the study as persons who self-report a cancer history) were asked to complete a supplemental questionnaire about the economic burden of cancer. Those reporting only a nonmelanoma skin cancer were not included in the cancer survivors group. All data were analyzed using statistical software, accounting for the complex survey design to obtain nationally representative estimates.

Medical costs (total annual medical expenditures) and productivity loss among cancer survivors were estimated adjusting for age, sex, race/ethnicity, number of MEPS priority conditions, marital status, and education.

Total annual medical costs, stratified by sex, were estimated using annual medical expenditures among cancer survivors and persons without a cancer history. The estimated total annual medical costs were also examined by the source of payment and service type. Lost productivity was estimated by assessing employment disability (being unable to work because of illness or injury), health-related missed work days, and days spent in bed because of ill health, stratified by sex.

Multivariable logistic regression was used to estimate the percentage of people unable to work because of illness or injury, adjusting for age, sex, race/ethnicity, number of MEPS priority conditions, and education. Negative binomial regression was used to estimate the number of missed work days and days in bed. All medical costs and productivity losses were adjusted to 2011 dollars.

Indicators of productivity loss among cancer survivors were also examined using data from the 2011 MEPS Experiences with Cancer Survivorship Survey, stratified by sex. The percentage of cancer survivors employed at any time since their diagnosis, changes in work because of cancer, and limitations in physical and mental tasks at work, productivity at work, and daily activities outside of work were estimated using multivariable logistic regression, adjusting for age, sex, race/ethnicity, and number of MEPS priority conditions.

Cancer survivors were more likely to be female, non-Hispanic white, in fair/poor health and insured and to have multiple chronic conditions compared with persons without a cancer history. During 2008 to 2011, male cancer survivors were found to have a mean annual medical expenditures of $8,091, compared with $3,904 among males without a cancer history.

Female survivors had mean annual medical expenditures of $8,412, compared with $5,119 among females without a cancer history.

Among survivors, private health insurance was the largest source of payment ($3,003 and $3,899 for males and females, respectively), followed by Medicare.

Ambulatory care medical services accounted for the largest share ($2,640 and $3,187) among survivors, followed by inpatient care ($1,722 and $1,843).

Among male cancer survivors, the per capita mean annual productivity loss was $3,719, compared with $2,260 among males without a cancer history. For female survivors, the per capita mean annual productivity loss was $4,033, compared with $2,703 among those without a cancer history. Employment disability accounted for about 75 percent of productivity loss among male and female survivors.

Nearly one third of cancer survivors experienced limitations in their ability to perform usual daily activities outside of work, and 12 percent had impeded ability to perform mental tasks associated with usual daily activities. Among cancer survivors who were employed at any time since diagnosis, cancer and its treatment interfered with physical tasks (25%) and mental tasks (14%) required by the job, with nearly 25 percent of cancer survivors feeling less productive at work.

Although males were more likely than females to have been employed since their diagnosis (62% and 55%, respectively), among those employed, females were significantly more likely to make changes in work because of cancer than males were (48% and 34%, respectively).

Back to Top | Article Outline

Discussion

The results of this analysis indicate that overall, cancer survivors had total annual medical expenditures estimated at $4,187 more for males and $3,293 more for females, compared with those of persons without a cancer history. These estimates were adjusted for age, sex, race/ethnicity, number of MEPS priority conditions, marital status, and education.

These findings add to the growing concerns about the costs of cancer treatment and their negative impact on cancer survivors and their families. For example, a recent study reported that persons diagnosed with cancer are at higher risk for bankruptcy than those without a cancer history.7

In 2012, the National Cancer Policy Forum of the Institute of Medicine (IOM) convened a workshop, “Delivering Affordable Cancer Care in the 21st Century”8 to discuss the drivers of current and projected costs of cancer care and potential ways to curtail these costs and maintain high-quality care. In 2009, before the IOM workshop, the American Society of Clinical Oncology published a guidance statement on the cost of cancer care.9

Overall, these efforts underscore the growing recognition by medical professionals, including clinical oncologists, of the important role they play in reducing the cost of cancer care for cancer survivors. A 2013 IOM publication, “Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis,” highlighted the importance of information about cancer costs and of quantifying the economic issues encountered by cancer survivors and their families.

Although many cancer survivors return to work and remain productive, for nearly a third of survivors, cancer and the lasting and late effects of treatment interfere with usual daily activities outside of work. Many of these survivors are in poor health. These survivors might be returning to work to maintain adequate health insurance coverage and pay for cancer-related services not covered by insurance.

For instance, approximately 10 percent of survivors younger than age 65 in this analysis were uninsured (and therefore likely have incurred a larger personal financial burden) and might experience more financial barriers to needed care than survivors who have some source of payment for medical services. The provisions of the Affordable Care Act are expected to help improve this situation by increasing access to health insurance for millions of persons living in the United States, including cancer survivors.

Further, approximately 30 percent of survivors are disabled and not able to return to work or have decreased ability to work because of limitations in cognitive, mental, and physical functioning and psychological distress.10 These survivors are more likely to incur higher productivity losses than persons without a cancer history. These challenges, particularly those related to employment, might differ for men and women, as presented in this report.

Back to Top | Article Outline

Possible Limitations

The findings in this report are subject to at least five limitations:

  • First, because of inadequate sample size, these analyses were not stratified by cancer site or by time since diagnosis.
  • Second, other aspects of economic burden of illness were not included, such as the time spent receiving medical care, productivity losses for caregivers, and intangible costs associated with pain and suffering from cancer and its treatment. Therefore, the reported medical and productivity costs represent only a portion of the total economic burden of cancer to society, survivors, and their families.
  • Third, this analysis relied on self-reports of cancer diagnosis, which was not verified by medical records, and household-reported survey data, which are subject to measurement errors (e.g., underreporting).
  • Fourth, because the 2008-2011 MEPS response rates were less than 60 percent the findings might reflect, in part, nonresponse bias.
  • Finally, because the MEPS priority conditions were based on a count of 10 conditions, some of the burden attributable to cancer could be attributed to unmeasured comorbid conditions.

The data presented in this report summarize efforts of a new collaborative group, the Health Economics Research on Cancer Workgroup, to promote health economics research on cancer. The workgroup is composed of scientists from CDC, the National Cancer Institute, the Agency for Healthcare Research and Quality, the American Cancer Society, Emory University, and the Livestrong Foundation. The workgroup seeks to address key research gaps identified in IOM reports,4 including the need for national estimates of the burden of cancer, examining the financial impact of cancer on survivors and their families, and patterns of employment.

The findings from these studies will provide invaluable information to help improve the quality of the cancer survivorship experience and reduce the burden of cancer in the United States.

With the projected increase in the number of cancer survivors, the economic burden of cancer will also likely increase.3 Therefore, public health decision-makers, professional medical organizations, and other stakeholders might want to focus their efforts on factors that can help to reduce the burden of cancer in the general population, including the recurrence of cancer in cancer survivors. Some of these factors might include primary prevention efforts, such as quitting smoking, being physically active, and maintaining a healthy weight.

The economic data presented in this report investigating the economic consequences of surviving cancer highlight the need to develop comprehensive intervention programs to improve the quality of the cancer survivorship experience and decrease the economic burden of cancer survivorship in the United States.

Reprinted (slightly adapted) from Morbidity and Mortality Weekly Report 2014;63;505-510.

Back to Top | Article Outline

References

1. Howlander N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2011. Bethesda, MD: National Cancer Institute; 2014. Available at http://seer.cancer.gov/statfacts/html/all.html.
2. De Moor JS, Mariotto AB, Parry C, et al. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev 2013;22:561–570.
3. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML Projections of the cost of cancer care in the United States: 2010-2020. JNCI 2011;103:117–128.
4. Hewitt M, Greenfield S, Stovall E eds From cancer patient to cancer survivor: lost in transition. Washington, DC: National Academies Press; 2006.
5. Ng AK, Travis LB Second primary cancers: an overview. Hematol Oncol Clin North Am 2008;22:2710–2789.
6. Yabroff KR, Dowling E, Rodriguez J, et al. The Medical Expenditure Panel Survey (MEPS) experiences with cancer survivorship supplement. J Cancer Surviv 2012;6:407–419.
7. Ramsey S, Blough D, Kirchhoff A, et al. Washington state cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff 2013;32:61143–61152.
8. Institute of Medicine: Delivering affordable cancer care in the 21st century: workshop summary. Washington, DC: National Academies Press; 2013. Available at http://www.iom.edu/reports/2013/delivering-affordable-cancer-care-in-the-21st-century.aspx.
9. Meropol NJ, Schrag D, Smith TJ, et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol 2009;23:3868–3874.
10. Dowling EC, Chawla N, Forsythe LP, et al. Lost productivity and burden of illness in cancer survivors with and without other chronic conditions. Cancer 2013;119:3393–33401
© 2014 by Lippincott Williams & Wilkins, Inc.
Home  Clinical Resource Center
Current Issue       Search OT
Archives Get OT Enews
Blogs Email us!